Elevation Point Wealth Partners LLC Invests $6.18 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Elevation Point Wealth Partners acquired 12,323 Thermo Fisher Scientific shares worth approximately $6.18 million, while institutional investors collectively own 89.23% of the company.
• Analysts maintain a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41. Thermo Fisher recently exceeded quarterly earnings and revenue estimates, with revenue rising 10.5% year over year.
• TMO shares opened at $629.02, near their 52-week high of $643.99. The company declared a quarterly dividend of $0.47 per share, while insiders sold shares worth approximately $37.7 million during the last quarter.

Elevation Point Wealth Partners LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,323 shares of the medical research company's stock, valued at approximately $6,184,000.

Other large investors have also added to or reduced their stakes in the company. J. Stern & Co. LLP boosted its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. BlackRock Inc. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. Norges Bank purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $3,072,744,000. Bank of New York Mellon Corp acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $1,974,561,000. Finally, Auto Owners Insurance Co increased its position in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock worth $1,406,844,000 after purchasing an additional 2,423,706 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on TMO shares. Piper Sandler raised their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Royal Bank Of Canada upped their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Evercore set a $570.00 price target on Thermo Fisher Scientific in a report on Monday, July 6th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Finally, Sanford C. Bernstein began coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $629.02 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a market capitalization of $232.58 billion, a price-to-earnings ratio of 33.84, a price-to-earnings-growth ratio of 2.56 and a beta of 0.85. The business has a fifty day moving average of $542.53 and a 200 day moving average of $509.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,493 shares of company stock valued at $37,657,681 in the last quarter. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source